Cargando…

Memantine treatment for Japanese patients with moderate to severe Alzheimer’s disease: a meta-analysis of double-blind, randomized, placebo-controlled trials

PURPOSE: Although previous meta-analyses of randomized trials in the world literature have provided strong evidence that supports the efficacy and safety of memantine for the treatment of patients with Alzheimer’s disease (AD), it is unclear whether the drug is beneficial in the treatment of Japanes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kishi, Taro, Matsunaga, Shinji, Iwata, Nakao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214597/ https://www.ncbi.nlm.nih.gov/pubmed/30464475 http://dx.doi.org/10.2147/NDT.S187320

Ejemplares similares

Memantine Monotherapy for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
por: Matsunaga, Shinji, et al.
Publicado: (2015)

The effects of memantine on behavioral disturbances in patients with Alzheimer’s disease: a meta-analysis
por: Kishi, Taro, et al.
Publicado: (2017)

PT592. Memantine Monotherapy for Alzheimer’s Disease: A Systematic Review and Meta-analysis
por: Matsunaga, Shinji, et al.
Publicado: (2016)

Combination Therapy with Cholinesterase Inhibitors and Memantine for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
por: Matsunaga, Shinji, et al.
Publicado: (2015)

Memantine for the treatment of frontotemporal dementia: a meta-analysis
por: Kishi, Taro, et al.
Publicado: (2015)

Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
por: Kishi, Taro, et al.
Publicado: (2015)

Protection against Brain Atrophy by Anti-dementia Medication in Mild Cognitive Impairment and Alzheimer’s Disease: Meta-Analysis of Longitudinal Randomized Placebo-Controlled Trials
por: Kishi, Taro, et al.
Publicado: (2015)

Aripiprazole for the management of schizophrenia in the Japanese population: a systematic review and meta-analysis of randomized controlled trials
por: Kishi, Taro, et al.
Publicado: (2015)

Melatonin receptor agonists—ramelteon and melatonin—for bipolar disorder: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials
por: Kishi, Taro, et al.
Publicado: (2019)

Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan
por: Nakamura, Yu, et al.
Publicado: (2014)

Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population
por: Kishi, Taro, et al.
Publicado: (2017)

Efficacy of Memantine for Agitation in Alzheimer’s Dementia: A Randomised Double-Blind Placebo Controlled Trial
por: Fox, Chris, et al.
Publicado: (2012)

Cholinesterase Inhibitors for Lewy Body Disorders: A Meta-Analysis
por: Matsunaga, Shinji, et al.
Publicado: (2015)

Iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine
por: Kishi, Taro, et al.
Publicado: (2014)

Efficacy and tolerability of topiramate-augmentation therapy for schizophrenia: a systematic review and meta-analysis of randomized controlled trials
por: Okuyama, Yuji, et al.
Publicado: (2016)

The Safety, Tolerability, and Efficacy of Once-Daily Memantine (28 mg): A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients with Moderate-to-Severe Alzheimer’s Disease Taking Cholinesterase Inhibitors
por: Grossberg, George T., et al.
Publicado: (2013)

Effectiveness and safety of generic memantine hydrochloride manufactured in China in the treatment of moderate to severe Alzheimer's disease: a multicenter, double-blind randomized controlled trial
por: Zhu, Minjie, et al.
Publicado: (2013)

Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials
por: Kishi, Taro, et al.
Publicado: (2018)

The Behavioral Effects of Combination Therapy of Memantine and Acetylcholinesterase Inhibitors Compared with Acetylcholinesterase Inhibitors Alone in Patients with Moderate Alzheimer’s Dementia: A Double-Blind Randomized Placebo-Controlled Trial
por: Youn, HyunChul, et al.
Publicado: (2021)

Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer’s disease in the Netherlands
por: Hoogveldt, Bart, et al.
Publicado: (2011)

Synthesis and Comparison of the Meta-Analyses Evaluating the Efficacy of Memantine in Moderate to Severe Stages of Alzheimer’s Disease
por: Rive, Benoît, et al.
Publicado: (2013)

Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study
por: Veerman, S. R. T., et al.
Publicado: (2016)

Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials
por: Kishi, Taro, et al.
Publicado: (2021)

Memantine add on to citalopram in elderly patients with depression: A double-blind placebo-controlled study
por: Omranifard, Victoria, et al.
Publicado: (2014)

Anti-Dementia Drugs for Psychopathology and Cognitive Impairment in Schizophrenia: A Systematic Review and Meta-Analysis
por: Kishi, Taro, et al.
Publicado: (2018)

Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study
por: Moreau, Caroline, et al.
Publicado: (2013)

Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer’s disease
por: Puangthong, Umamon, et al.
Publicado: (2009)

Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial)
por: Knapp, Martin, et al.
Publicado: (2016)

Memantine as treatment for compulsivity in child and adolescent psychiatry: Descriptive findings from an incompleted randomized, double-blind, placebo-controlled trial
por: Niemeyer, Larissa, et al.
Publicado: (2022)

DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease – a multicentre RCT
por: Jones, Rob, et al.
Publicado: (2009)

Efficacy of Memantine, Donepezil, or Their Association in Moderate-Severe Alzheimer's Disease: A Review of Clinical Trials
por: Molino, Ivana, et al.
Publicado: (2013)

Early prediction of blonanserin response in Japanese patients with schizophrenia
por: Kishi, Taro, et al.
Publicado: (2014)

The Alzheimer's disease THErapy with NEuroaid (ATHENE) study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild-to-moderate Alzheimer's disease stable on cholinesterase inhibitors or memantine—A randomized, double-blind, placebo-controlled trial
por: Chen, Christopher L.H., et al.
Publicado: (2019)

Memantine for Refractory Obsessive-Compulsive Disorder: Protocol for a Pragmatic, Double-blind, Randomized, Parallel-Group, Placebo-Controlled, Monocenter Trial
por: Maraone, Annalisa, et al.
Publicado: (2023)

Efficacy and safety of lithium and lamotrigine for the maintenance treatment of clinically stable patients with bipolar disorder: A systematic review and meta‐analysis of double‐blind, randomized, placebo‐controlled trials with an enrichment design
por: Oya, Kazuto, et al.
Publicado: (2019)

Memantine: efficacy and safety in mild-to-severe Alzheimer’s disease
por: Tampi, Rajesh R, et al.
Publicado: (2007)

A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease
por: Deardorff, William James, et al.
Publicado: (2016)

Combined application of tenuigenin and β-asarone improved the efficacy of memantine in treating moderate-to-severe Alzheimer’s disease
por: Chang, Wenguang, et al.
Publicado: (2018)

Virtual Therapy with the NMDA Antagonist Memantine in Hippocampal Models of Moderate to Severe Alzheimer’s Disease, In Silico Trials
por: Świetlik, Dariusz, et al.
Publicado: (2022)

Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer’s disease
por: Cummings, Jeffrey L., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_h9v1qpcjnfakoa7odorn1g4mab